A study published in the journal Nature Medicine examined the effectiveness of bispecific T cell activators (blinatumomab and teclistamab) in patients with autoimmune connective tissue diseases who did not respond to standard therapy. The study included ten patients – five with treatment-refractory antisynthetase syndrome and five with treatment-refractory systemic sclerosis. Bispecific T cells improved disease activity in both groups of patients. The drugs were well tolerated without serious side effects. These results suggest that bispecific T cell activators may represent a new treatment option for patients with autoimmune connective tissue diseases unresponsive to conventional therapy. This is a preliminary study on a small number of patients, which paves the way for further research into this treatment method.